28466-65-1

Usage

Uses

Used in Pharmaceutical Applications:
1-(2-phenylethyl)-1H-pyrazol-4-amine is used as a therapeutic agent for the potential treatment of depression. Its ability to modulate neurotransmitter levels, particularly dopamine, norepinephrine, and serotonin, makes it a promising candidate for addressing the underlying neurochemical imbalances associated with this mood disorder.
1-(2-phenylethyl)-1H-pyrazol-4-amine is also used as a potential treatment for attention deficit hyperactivity disorder (ADHD). Its psychostimulant effects, which include increased locomotor activity and stimulation, may help alleviate some of the core symptoms of ADHD, such as inattention, impulsivity, and hyperactivity.
Used in Recreational Applications:
In the recreational context, 1-(2-phenylethyl)-1H-pyrazol-4-amine is used as a psychoactive substance. Its stimulating effects and ability to increase locomotor activity make it a potential candidate for use as a recreational drug. However, it is important to note that the safety, efficacy, and legal status of PPAP for recreational use are subjects that require further research and regulation.
It is crucial to emphasize that the use of 1-(2-phenylethyl)-1H-pyrazol-4-amine in any context should be approached with caution, as its long-term effects, potential for abuse, and interactions with other substances are not yet fully understood. Further research and clinical trials are necessary to establish the safety and efficacy of PPAP in various applications.

Upstream product

• 103-63-9 1-phenyl-2-bromoethane 
• 585-71-7 (1-bromoethyl)benzne 
• 28469-23-0 4-nitro-1-(2-phenylethyl)-1H-pyrazole 

Downstream Products

• 1258557-68-4 (1S,2S,3R,4R)-3-[(5-chloro-2-{[1-(2-phenylethyl)-1H-pyrazol-4-yl]amino}pyrimidin-4-yl)amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide 
• 1258558-14-3 (1R,2R,3S,5R)-2-[(5-chloro-2-{[1-(2-phenylethyl)-1H-pyrazol-4-yl]amino}pyrimidin-4-yl)amino]-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxamide 

Relevant academic research and scientific papers

AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS

The present invention relates to pyrazole and imidazole derivatives of formula (I) wherein U, V, L, X, Y, R1, (R2)n and (R3)m and ring A are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

PYRIMIDINE INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A1, A2, A3, A4, X and Y are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora and KDR.

ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS

Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mekl, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2